stockrow
Friday 6 November 2026
Export GLAS’s income statement to Excel — free account
Glass House Brands Inc.
GLAS Healthcare Drug Manufacturers Specialty & Generic
Glass House Brands Inc.’s revenue for fiscal 2025 (year ended December 2025) was $182.0 million, down 9.41% from fiscal 2024.
- Revenue
- −1.24%
- EPS
- −320.0%
- Free cash flow
- −123.4%
- Total debt
- −17.2%
Quarter to June 2026, against a year earlier
2.18
0.05
−2.24%
Follow GLAS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+7 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.37 | 3.98 | 4.00 | 6.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(122.60) | (195.93) | (60.48) | 6,446.33 | |
P/B ratio |
6.95 | 8.83 | 8.37 | 15.89 | |
Price to Tangible BV |
8.01 | 8.92 | 9.70 | 16.09 | |
EV/Sales |
3.61 | 4.30 | 4.25 | 6.73 | |
EV/EBITDA |
49.28 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
28.46 | 68.29 | (271.76) | (58.57) | |
EV/FCF |
(166.08) | (50.40) | (28.41) | (32.37) | |
Quick Ratio |
1.03 | 0.46 | 0.79 | 0.55 | |
Current Ratio |
2.24 | 1.78 | 1.85 | 1.33 | |
Net Debt/EBITDA |
(5.93) | (6.83) | (4.29) | 46.53 | |
Debt/Assets |
21.91% | 21.69% | 21.12% | 17.78% | |
Debt/Equity |
0.79 | 0.84 | 0.81 | 0.77 | |
Asset Turnover |
0.59 | 0.58 | 0.56 | 0.55 | |
Operating CF/Net income |
0.33 | 0.20 | 0.59 | (0.02) | |
Capex/Depreciation |
(2.16) | (0.54) | (0.88) | (0.56) | |
Interest Coverage |
(6.26) | (11.40) | (11.08) | (4.77) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
43.25% | 46.76% | 43.14% | 29.23% | |
Intangible Assets out of Total Assets |
0.04 | 0.00 | 0.04 | 0.00 | |
Share Based Compensation of Revenue |
10.61% | 8.36% | 11.16% | 8.96% | |
Graham Net Nets |
(0.25) | (0.23) | (0.23) | (0.15) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.93%) | (6.21%) | (7.35%) | (5.85%) | |
Free Cash Flow Yield |
(0.64%) | (2.14%) | (3.74%) | (3.19%) | |
Revenue per Share |
0.47 | 0.62 | 0.47 | 0.53 | |
Operating CF per Share |
(0.06) | (0.05) | (0.13) | 0.00 | |
Capex per Share |
(0.10) | (0.03) | (0.04) | (0.02) | |
Free Cash Flow per Share |
(0.17) | (0.07) | (0.18) | (0.02) | |
Cash per Share |
0.32 | 0.15 | 0.28 | 0.21 | |
Shareholders Equity per Share |
1.08 | 1.00 | 0.98 | 0.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.08 | 1.00 | 0.98 | 0.82 | |
Free Cash Flow |
(13.69) | (5.88) | (15.30) | (1.93) | |
Working Capital |
41.11 | 29.79 | 34.15 | 17.85 | |
Capital Expenditures |
(8.63) | (2.18) | (3.55) | (2.11) | |
Net Current Asset Value |
(156.22) | (168.71) | (166.05) | (169.53) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.22 | 0.04 | 0.09 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.99 | 6.17 | 7.92 | 10.80 | |
Average Payables |
27.85 | 29.69 | 34.39 | 37.79 | |
Average Inventory |
14.11 | 19.28 | 23.61 | 26.85 | |
Average Assets |
311.80 | 314.53 | 318.47 | 323.97 | |
Average Common Equity |
78.17 | 79.90 | 85.25 | 86.58 |
Columns are period end dates · fundamentals updated 2 Nov 2026